All Stories

  1. Molecular medicine and neurodegenerative diseases
  2. Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione γ-Secretase Modulators
  3. Investigating γ-secretase protein interactions in live cells using active site-directed clickable dual-photoaffinity probes
  4. Development of CBAP-BPyne, a probe for γ-secretase and presenilinase
  5. Discovery of selective 2,4-diaminopyrimidine-based photoaffinity probes for glyoxalase I
  6. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012
  7. An Isotopically Tagged Azobenzene‐Based Cleavable Linker for Quantitative Proteomics
  8. P4–298: Understanding the target and evaluating the consequences of gamma‐secretase modulation from in vitro models to higher‐order species
  9. Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease
  10. The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)
  11. Development of clickable active site-directed photoaffinity probes for γ-secretase
  12. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
  13. Target of γ-secretase modulators, presenilin marks the spot
  14. O-Hydroxyacetamide Carbamates as a Highly Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
  15. Piperidine Acetic Acid Based γ-Secretase Modulators Directly Bind to Presenilin-1
  16. Recent advances in medicinal chemistry
  17. Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder
  18. Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
  19. Novel γ-secretase modulators: a review of patents from 2008 to 2010
  20. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
  21. Modern Drug Synthesis
  22. P1‐296: Gamma‐secretase inhibitors and gamma‐secretase modulators differentially regulate amyloid‐beta 42 peptide generation in native brain membrane preparations from multiple species
  23. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors
  24. Chemical Proteomic Technologies for Drug Target Identification
  25. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
  26. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH)
  27. Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
  28. Structure-guided inhibitor design for human FAAH by interspecies active site conversion
  29. Synthesis of fluorinated 1,8-naphthyridinone derivatives
  30. Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity
  31. Synthesis of monofluorinated 1-(naphthalen-1-yl)piperazines
  32. Synthesis of chromanyl and dihydrobenzofuranyl piperazines
  33. The Art of Drug Synthesis
  34. Neuraminidase Inhibitors for Influenza: Oseltamivir Phosphate (Tamiflu ® ) and Zanamivir (Relenza ® )
  35. Contemporary Drug Synthesis
  36. Catalytic Enantioselective Amination of Enolsilanes Using C2-Symmetric Copper(II) Complexes as Chiral Lewis Acids
  37. Duocarmycin SA Shortened, Simplified, and Extended Agents:  A Systematic Examination of the Role of the DNA Binding Subunit
  38. Reversed and Sandwiched Analogs of Duocarmycin SA:  Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis
  39. pH Dependence of the rate of DNA alkylation for (+)-duocarmycin SA and (+)-CCBI-TMI
  40. Examination of the role of the duocarmycin SA methoxy substituents: Identification of the minimum, fully potent DNA binding subunit
  41. CC‐1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies
  42. CC-1065 CBI analogs: an example of enhancement of DNA alkylation efficiency through introduction of stabilizing electrostatic interactions
  43. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.
  44. Second Definitive Test of Proposed Models for the Origin of the CC-1065 and Duocarmycin DNA Alkylation Selectivity
  45. (+)- and ent-(-)-Duocarmycin SA and (+)- and ent-(-)-N-BOC-DSA DNA Alkylation Properties.Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents
  46. Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins
  47. Molecular basis for sequence selective DNA alkylation by (+)- and ent-(−)-CC-1065 and related agents: Alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity
  48. Evaluation of functional Analogs of CC-1065 and the Duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (C2BI) alkylation subunit
  49. Alkyne insertion reactions of metal-carbenes derived from enynyl-.alpha.-diazoketones [R'CN2COCR2CH2C.tplbond.C(CH2)n-2CH:CH2]